Merck & Co Inc

• Macroeconomic tailwinds and risk-on sentiment drove Moderna's strong upward rally and volatility. • Positive late-stage clinical data for intismeran expanded valuation expectations for oncology. • Analyst upgrades and institutional demand absorbed selling pressure from routine insider sales.

• Novo Nordisk partnered with Orbis Medicine for AI-driven oral cardiometabolic drug discovery. • European regulators issued a favorable marketing recommendation for Frehemgo in hemophilia A. • The company reported $46.70B in annual revenue and $15.48B in net profit.

• Moderna experienced upward volatility driven by renewed institutional buying and consolidation. • Phase 3 trial results for intismeran autogene validated its oncology platform. • Latest annual revenue is $1.94B with a net loss of $-2.82B.

• Moderna announced a proposed two billion dollar convertible senior notes private placement. • The pullback followed profit-taking after positive Phase 3 clinical trial developments. • Annual revenue stands at $1.94 billion alongside a net profit of $-2.82 billion.

• Novo Nordisk faced downside pressure due to margin compression and pricing dynamics. • Intense competition from rival therapies heightened sensitivity to market share trends. • The stock reported an annual revenue of $46.70B and net profit of $15.48B.

• Summit Therapeutics shares rose following positive Phase 3 trial results for ivonescimab. • The HARMONi-GI1 study met its primary overall survival endpoint in biliary tract cancer. • Summit reports zero annual revenue and a net loss of $1.08 billion.